| Net Cash Provided by (Used in) Operating Activities |
$115,940 |
USD |
73% |
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Financing Activities |
$0 |
USD |
|
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Investing Activities |
$0 |
USD |
|
Q1 2025 |
Q1 2025 |
| Common Stock, Shares Authorized |
400,000,000 |
shares |
0% |
Q3 2025 |
Q3 2025 |
| Common Stock, Shares, Issued |
60,354,539 |
shares |
0% |
Q3 2025 |
Q3 2025 |
| Common Stock, Par or Stated Value Per Share |
0 |
USD/shares |
0% |
Q3 2025 |
Q3 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$115,392 |
USD |
74% |
Q1 2025 |
Q1 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$49,268 |
USD |
-91% |
Q3 2025 |
Q3 2025 |
| Interest Paid, Excluding Capitalized Interest, Operating Activities |
$0 |
USD |
|
Q1 2025 |
Q1 2025 |
| Deferred Tax Assets, Valuation Allowance |
$2,383,000 |
USD |
125% |
Q4 2024 |
FY 2024 |
| Deferred Tax Assets, Gross |
$2,383,000 |
USD |
13% |
Q4 2024 |
FY 2024 |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent |
$3,143,010 |
USD |
-109% |
Q3 2025 |
Q3 2025 |
| Additional Paid in Capital |
$28,115,899 |
USD |
0% |
Q3 2025 |
Q3 2025 |
| Deferred Tax Assets, Net of Valuation Allowance |
$0 |
USD |
-100% |
Q4 2024 |
FY 2024 |
| Share-based Payment Arrangement, Expense |
$0 |
USD |
|
Q1 2025 |
Q1 2025 |